Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2025 17:14 ET | Source: Beta Bionics, Inc.

Beta Bionics Files Registration Statement for Proposed Initial Public Offering

Beta Bionics, Inc., a leader in the development of advanced diabetes management solutions, announced that it has filed a Form S-1 with the SEC.
January 04, 2023 12:00 ET | Source: Beta Bionics, Inc.

Beta Bionics Appoints Dr. Steven Russell as Chief Medical Officer in Preparation for the Commercial Launch of the iLet Bionic Pancreas System

CONCORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a clinical-stage medical technology company — announced the appointment of Steven Russell, MD, Ph.D., to the role of Chief...
August 15, 2022 16:00 ET | Source: Beta Bionics, Inc.

Beta Bionics Appoints Sean Saint as CEO and Board Member

Caution: The iLet® Bionic Pancreas and iLet Duo™ are investigational devices limited by Federal (or United States) law to investigational use. Not available for sale. CONCORD, Mass., Aug. 15, 2022 ...
June 09, 2022 14:00 ET | Source: Beta Bionics, Inc.

The Insulin-Only Bionic Pancreas Pivotal Trial Showed Consistent Mean HbA1c Reductions Across a Variety of Subgroups at ADA’s 82nd Scientific Sessions

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. The randomized Insulin-Only Bionic Pancreas...
June 01, 2022 05:00 ET | Source: Beta Bionics, Inc.

Pivotal Trial Results of the iLet® Bionic Pancreas to Be Presented at the ADA’s 82nd Scientific Sessions

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Roy W. Beck will moderate a session: The...
May 10, 2022 05:00 ET | Source: Beta Bionics, Inc.

Beta Bionics Appoints Gilad Glick to the Board of Directors and Veena Rao, Ph.D. as Chief Commercial Officer

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Gilad Glick, former Chief Executive Officer,...
April 30, 2022 04:00 ET | Source: Beta Bionics, Inc.

The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes

The trial achieved key primary and secondary endpoints, demonstrating improved outcomes over standard of care for people living with type 1 diabetes.The study population — 440 adults and children 6...
April 25, 2022 05:00 ET | Source: Beta Bionics, Inc.

Pivotal Trial Results of the iLet® Bionic Pancreas To Be Presented at ATTD

Dr. Steven J. Russell will present the results from the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial at the International Conference on Advanced Technologies & Treatments for...
March 02, 2022 16:15 ET | Source: Beta Bionics, Inc.

Beta Bionics Announces Executive Leadership and Board Transitions in Preparation for Commercialization of the iLet® Bionic Pancreas System

Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Ed Damiano, President & CEO of Beta...
May 06, 2021 16:00 ET | Source: Beta Bionics, Inc.

Beta Bionics Announces Appointment of Christy Jones to Board of Directors

IRVINE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today...